menu
BCM - Baylor College of Medicine

Giving life to possible

Clinical Trials

Administration of TGF-b Resistant LMP-Specific Cytotoxic T-Lymphocytes to Patients with Relapsed EBV-Positive Lymphoma (H-17946) (H-17946)

H-17946: Administration of TGF-b Resistant LMP-Specific Cytotoxic T-Lymphocytes to Patients with Relapsed EBV-Positive Lymphoma (TGF-Beta): This study uses EBV specific T-Lymphocytes with a gene inserted to render them resistant to TGF-b to treat lymphoma.

For more information:http://www.clinicaltrials.gov/ct2/show/NCT00675571